Previous close | 3.6350 |
Open | 3.8400 |
Bid | 3.8500 x 900 |
Ask | 3.9000 x 400 |
Day's range | 3.7900 - 3.9200 |
52-week range | 1.3000 - 4.4500 |
Volume | |
Avg. volume | 1,861,552 |
Market cap | 47.494M |
Beta (5Y monthly) | 0.93 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.2600 |
Earnings date | 02 May 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 12.60 |
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript March 27, 2024 Cellectar Biosciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. And welcome to Cellectar Biosciences 2023 Yearend Earnings Call. Today’s call is being recorded. Before […]
Q4 2023 Cellectar Biosciences Inc Earnings Call
Management to host a conference call today at 8:30 am ETFLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the year ended December 31, 2023, and provided a corporate update. “2023 was a year of significant progress for Cellectar, culminating in the January announceme